United Services Automobile Association Acquires New Shares in Repligen Corporation $RGEN

Key Points

• United Services Automobile Association has acquired 3,459 shares of Repligen Corporation valued at approximately $461,000 during the first quarter of this year.
• Repligen reported quarterly earnings of $0.37 per share, missing the consensus estimate of $0.40, while revenue increased by 14.8% year-over-year to $182.37 million.
• Several analysts have issued ratings for Repligen, with target prices ranging from $130.00 to $205.00, reflecting a consensus rating of "Moderate Buy."

United Services Automobile Association acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 3,459 shares of the biotechnology company's stock, valued at approximately $461,000.

Several other hedge funds also recently modified their holdings of the company. Fred Alger Management LLC boosted its holdings in shares of Repligen by 21.6% during the 1st quarter. Fred Alger Management LLC now owns 437,037 shares of the biotechnology company's stock valued at $55,609,000 after acquiring an additional 77,530 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock valued at $18,067,000 after acquiring an additional 20,375 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock valued at $814,000 after acquiring an additional 6,238 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Repligen by 233.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock valued at $1,172,000 after acquiring an additional 6,448 shares in the last quarter. Finally, Scientech Research LLC bought a new position in Repligen during the 1st quarter worth $1,837,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Stock Performance

RGEN stock opened at $120.23 on Thursday. The stock has a 50-day moving average price of $121.16 and a 200-day moving average price of $128.66. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The firm has a market cap of $6.76 billion, a PE ratio of -480.90, a price-to-earnings-growth ratio of 2.18 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. During the same period last year, the business posted $0.40 earnings per share. The business's revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on RGEN shares. Stephens raised Repligen to an "overweight" rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Finally, Evercore ISI lowered their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus target price of $169.55.

Insider Buying and Selling at Repligen

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.